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Clinical Infectious Diseases
S U P P L E M E N T A R T I C L E
Sustained Effectiveness of the Maternal Pertussis
Immunization Program in England 3 Years Following
Introduction
Gayatri Amirthalingam,1 Helen Campbell,1 Sonia Ribeiro,1 Norman K. Fry,2 Mary Ramsay,1 Elizabeth Miller,1 and Nick Andrews3
1Immunisation, Hepatitis and Blood Safety Department, 2Respiratory and Vaccine Preventable Bacterial Reference Unit, and 3Statistics, Modelling and Economics Department, Public Health England,
London, United Kingdom
The effectiveness of maternal immunization in preventing infant pertussis was ﬁrst demonstrated in England, 1 year after the pro-
gram using diphtheria–tetanus–5-component acellular pertussis–inactivated polio vaccine (dT5aP-IPV) was introduced in 2012.
Vaccine effectiveness against laboratory-conﬁrmed pertussis has been sustained >90% in the 3 years following its introduction, de-
spite changing to another acellular vaccine with different antigen composition. Consistent with this, disease incidence in infants <3
months of age has remained low despite high activity persisting in those aged 1 year and older. Vaccine effectiveness against infant
deaths was estimated at 95% (95% conﬁdence interval, 79%–100%). Additional protection from maternal immunization is retained
in infants who received their ﬁrst dose of the primary series. There is no longer evidence of additional protection from maternal
vaccination after the third infant dose. Although numbers are small and ongoing assessment is required, there is no evidence of
increased risk of disease after primary immunization in infants whose mothers received maternal vaccination.
Keywords. maternal pertussis vaccination; vaccine effectiveness.
Pertussis resurgences have been reported in recent years from a
number of countries with longstanding vaccination programs.
Global efforts have therefore focused on better understanding
the underlying reasons for the increases and consideration of
strategies for optimizing protection of young infants, who are
at highest risk of severe disease and death. In the 2015 World
Health Organization (WHO) pertussis position paper, the evi-
dence for a range of additional strategies including cocooning
and maternal immunization were reviewed, drawing from the
experience of countries in which these strategies had been im-
plemented with varying degrees of success [1].
Maternal immunization has been recommended in a number
of countries including the United Kingdom, the United States,
Australia, Argentina, Belgium, and Spain [2–7]. In the United
Kingdom, an emergency program to offer pertussis vaccination
to pregnant women was introduced in October 2012, in re-
sponse to a rise in hospitalizations and deaths among unimmu-
nized infants <3 months of age, with 14 pertussis-related infant
deaths reported in the 2012 peak [8].Many other countries have
also observed an increasing burden of infant disease, with an
average of 3055 infant pertussis cases and >19 infant deaths
reported each year in the United States since 2004 [9]. The
recommendation to offer a low-dose diphtheria–tetanus–5-
component acellular pertussis–inactivated polio combination
vaccine (dT5aP-IPV) to women in every pregnancy, ideally be-
tween 28 and 32 weeks, was considered the best way to protect
infants from birth, which is through passive immunization from
transplacentally derived maternal antibodies. The United King-
dom was the ﬁrst country to demonstrate high levels of protec-
tion against disease in infants from maternal immunization
using 2 different methodological approaches. Vaccine effective-
ness in the ﬁrst year of the program was estimated to be >90%
for infants <2 months of age, whose mothers received dT5aP-
IPV at least 1 week prior to delivery [10, 11].This was further
supported by ecological evidence of a direct impact on labora-
tory-conﬁrmed reports and hospitalizations in the target age
group [10]. The safety of the maternal pertussis immunization
program has also been supported by the ﬁndings of a large ob-
servational study in the United Kingdom, which did not iden-
tify an increased risk for a range of maternal, fetal, and neonatal
outcomes among almost 18 000 vaccinated pregnant women
and their infants [12]. In 2014, in the face of continuing raised
levels of pertussis activity in the population and good evidence
supporting the safety and effectiveness of the program, the na-
tional advisory committee, the Joint Committee on Vaccination
and Immunisation (JCVI), advised that this outbreak response
measure should continue for a further 5 years [13]. In the Unit-
ed Kingdom, vaccines for the national program are centrally
procured and distributed and in July 2014, the vaccine product
being offered to pregnant women changed from dT5aP-IPV
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(pertussis toxin [PT]: 2.5 µg; ﬁlamentous hemagglutinin
[FHA]: 5 µg; pertactin [PRN]: 3 µg; ﬁmbriae types 2 and 3
[FIM]: 5 µg) to diphtheria–tetanus–3-component acellular per-
tussis (dT3aP-IPV) (PT: 8 µg; FHA: 8 µg; PRN: 2.5 µg).
Despite the reassuring data on safety and effectiveness of ma-
ternal immunization, one of the key remaining questions has
been the impact of interference from maternally derived anti-
bodies on the infants’ immune response and the resultant risk
of disease among older fully vaccinated infants and toddlers.
While a number of published studies from the United King-
dom, Belgium, and North America have demonstrated blunting
of pertussis responses and other antigens in the routine pro-
gram in infants born to vaccinated mothers, the clinical signiﬁ-
cance of these effects remains unknown due to a lack of any
agreed correlates of protection for pertussis [14–17]. In this ar-
ticle, we update the previously published estimates of vaccine
effectiveness (VE) of the maternal program in England,
3 years following its introduction, and provide the ﬁrst estimates
for the effectiveness of the maternal program on infant deaths
and the comparative effectiveness of dT5aP-IPV and dT3aP-
IPV on infant disease. An early assessment of the potential im-
pact of blunting on clinical disease is also presented.
METHODS
Data Sources
Vaccine Coverage
In England, the delivery of the maternal pertussis vaccination
program predominantly occurs in general practice and, there-
fore, primary care data provide the most accurate and reliable
source of coverage data. In England, this can be derived from
2 primary care data sets. The ﬁrst source is the routine collection
(Immform), which measures coverage at national and subna-
tional levels on a monthly basis using data held on computer-
ized general practice records. Since April 2014, this has moved
from a manual to an automated extraction with participation of
>90% of general practices in England. In each survey month, the
denominator is the number of pregnant women with an esti-
mated date of delivery in that month and the numerator is
the number of women who received pertussis vaccine after 28
weeks of gestation.
The second data source is a sentinel primary care data source,
the Clinical Practice Research Datalink (CPRD), which repre-
sents approximately 6% of the UK population and includes
520 English general practices. The CPRD has been used to eval-
uate the maternal program in England and the methods previ-
ously described [10]. Data from the CPRD were extracted in
November 2015 and coverage was calculated by week of the
child’s birth for the period 1 October 2012 to 31 August
2015. The cohort was deﬁned as any woman with a READ
code for a live birth from 1 October 2012. For each week, the
denominator was the number of women from participating
practices that delivered a live infant in that week; the numerator
was the number of women who received a pertussis vaccine dur-
ing pregnancy. Only pertussis vaccines recorded as adminis-
tered between 300 days prior to a birth and up to 8 weeks
after birth were counted. The additional beneﬁt of the CPRD
over the routine collection is that the precise timing of vaccina-
tion during pregnancy can be derived. To determine likely vac-
cine product administered, 1 July 2014 was used as the switch
from dT5aP-IPV to dT3aP-IPV. As data are analyzed according
to the child’s date of birth, there is a period during which chil-
dren born may have had mothers vaccinated by either vaccine.
Laboratory-Conﬁrmed Pertussis
In England, Public Health England (PHE) is responsible for the
national surveillance of vaccine-preventable infections with de-
tailed individual follow-up of all laboratory-conﬁrmed pertussis
cases. Laboratory conﬁrmation can either occur at the local hos-
pital microbiology laboratory (culture); through the regional
PHE laboratory network (polymerase chain reaction available
through the regional network since July 2014 for all age groups,
previously only offered for hospitalized infants by the national
reference laboratory); or at the national reference laboratory (se-
rological testing available since 2001 for all age groups and,
since January 2013, oral ﬂuid testing for suspected cases initially
aged 8–16 years and extended to those aged 5–16 years from
July 2013). Both serology and oral ﬂuid testing are based on
demonstrating high anti-PT immunoglobulin G titers above a
predeﬁned threshold considered indication of recent infection
and may be confounded by pertussis vaccination within the pre-
vious year [18].
All laboratory-conﬁrmed cases are followed up with the pa-
tients’ general practitioner to collect additional clinical and ep-
idemiological data including vaccination history and, for infants
born after 1 October 2012, the maternal vaccination status.
Since July 2014, with changes to the vaccine product being of-
fered through the national program, additional information on
the vaccines administered is collected for both the childhood
course and maternal vaccination where applicable.
Pertussis-Related Deaths
Pertussis deaths are reconciled from the following data sources:
registered deaths from the Ofﬁce of National Statistics; deaths
identiﬁed from the routine follow-up of laboratory-conﬁrmed
reports; and those identiﬁed in the Hospital Episode Statistics
dataset and on HPZone (InFact UK Ltd), a secure Web-based
information system used to record local public health manage-
ment of individual cases of infectious diseases.
Statistical Analysis
Maternal Vaccine Effectiveness Against Infant Disease and Death
Vaccine effectiveness against laboratory-conﬁrmed infant dis-
ease was calculated using the screening method where VE is 1
minus the odds of vaccination in cases (maternal vaccine status)
divided by the odds of vaccination in the matched population.
Maternal Pertussis Vaccination Effectiveness • CID 2016:63 (Suppl 4) • S237
Statistically this was done by logistic regression with an offset
for the logit of the matched population coverage. Detailed
methods have been previously described [10, 19].
For the analysis, the expected coverage in the mother was de-
termined for each conﬁrmed case using the CPRD dataset
matched on the week of birth of the baby and the birth cohort
of the mother (pre-1985, 1985–1989, 1990 and later). If moth-
er’s date of birth was unknown, the average coverage was used.
For the primary analysis, when calculating expected vaccine
coverage, any vaccine given within 7 days of birth was excluded
from the calculation. Similarly, any cases whose mothers were
vaccinated within 7 days of birth were not included. Cases
were included if the age at onset was known, or otherwise if
date of specimen collection was before the age of 24 months
(≤731 days). VE was assessed for cases with onset/sample
aged ≤62 days and cases with onset/sample aged ≤93 days as
long as they had not received their ﬁrst routine dose within
7 days of onset/sample.
To account for differences observed between CPRD coverage
and Immform coverage, a sensitivity analysis was done with
coverage reduced by a relative 20% (eg, 70% reduces to 56%)
to more closely match Immform coverage.
Analysis was undertaken to calculate the following VE mea-
sures: (1) maternal VE against infant disease; (2) maternal VE
by timing of vaccination; (3) maternal VE against infant death
from pertussis; and (4) maternal VE against infant disease for
dTaP5-IPV and dTaP3-IPV vaccines.
Maternal Vaccine Effectiveness in Infants Commencing Primary
Infant Series
To address the question of whether maternal vaccination may
have a detrimental effect on responses to primary vaccination,
the VE of the maternal vaccine in children who have received
primary vaccine doses was assessed. An infant dose was counted
if given >7 days prior to onset/sample date. Sample date may be
weeks after onset date, so children with only a sample date may
in fact have had onset prior to vaccine doses. Children up to 23
months of age were included and maternal VE was assessed
after the infant had received 1, 2, and 3 primary doses. An ad-
ditional analysis using only cases with a known onset date was
done to reduce possible misclassiﬁcation of vaccination status.
RESULTS
Maternal Vaccine Coverage
The coverage of the maternal program in England achieved in
the ﬁrst year of the program has been sustained over the subse-
quent 2 years, with monthly coverage collected through the na-
tional Immform dataset indicating coverage sustained at
between 50% and 62% from January 2013 to December 2015
(Figure 1). However, there does appear to be ﬂuctuation over
Figure 1. Maternal pertussis vaccine coverage, England, October 2012–August 2013, Clinical Practice Research Datalink (CPRD) and Immform. Denominator for CPRD is
number of women delivering a live infant, by week of birth; denominator for Immform is number of pregnant women with an estimated date of delivery, each month. Abbre-
viations: dT3aP, diphtheria–tetanus–3-component acellular pertussis vaccine; dT5aP, diphtheria–tetanus–5-component acellular pertussis vaccine; IPV, inactivated polio
vaccine.
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the year, particularly evident in 2013 and 2014, with coverage
increasing during September to January and lower between
April to August.
From the CPRD, a total of 72 781 live births from 1 October
2012 until 31 August 2015 were obtained. Vaccination coverage
by week of birth and timing of vaccination relative to the birth is
shown in the ﬁgure. Coverage reached a peak of 78% in mothers
giving birth in the ﬁrst week of January 2013, but has since
shown ﬂuctuations similar to the pattern observed through
the routine Immform collection, with coverage higher over
the winter months (70% in December 2013) and lower in the
summer months (60% in those giving birth in August 2013).
Coverage increased in 2015 to 70% and has remained stable
to the end of August 2015.
Following introduction of the vaccine programme, the ma-
jority (more than two-thirds) of women vaccinated received
vaccine at least 8 weeks prior to delivery. The ﬁgure 1 also
shows which vaccine the mothers will have received and a
period of uncertainty from week 27 to week 38 (July to mid-
September 2014).
Impact on Disease Epidemiology
Pertussis incidence fell from a peak of 17.6 per 100 000 in 2012
to 8.6, 6.2, and 7.7 per 100 000 in 2013, 2014, and 2015, respec-
tively. In 2015, there was an increase in all age groups relative to
2014 totals (Figure 2) and in line with expected cycles in disease
incidence every 3–4 years. The average incidence of 7.5 per
100 000 in England over the 3 years following the introduction
of the maternal program was 1.8 times higher than the 4.1 per
100 000 population in the 3 years preceding the program’s in-
troduction. This overall increase in incidence relative to the pre-
2012 period was observed in all age groups 6 months and older
(Figure 2), with the combined 3-year comparator periods
(2009–2011 vs 2013–2015) increasing from 1.5 to 3.1 per
100 000 in those aged 6–11 months (2.1 times higher); 0.7 to
2.2 per 100 000 in those aged 1–4 years (3.1 times higher); 0.6
to 4.6 per 100 000 in those aged 5–9 years (7.7 times higher); 2.6
to 13.6 per 100 000 in those aged 10–14 years (5.2 times higher);
and 1.1 to 7.4 per 100 000 in those aged ≥15 years (6.7 times
higher). The greatest increase was observed in children aged
5–9 years of age who would have all received a complete
Figure 2. Incidence of laboratory-confirmed pertussis, by year and age group, England only, 1998–2015.
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primary and booster course of acellular pertussis–containing
vaccine from mid-2013 onward. The ascertainment of cases
aged 5–16 years has been enhanced with the availability of
oral ﬂuid testing from 2013: between 2013 and 2015 respective-
ly, 14%, 21%, and 29% of cases aged 5–9 years and 14%, 15%,
and 19% of those aged 10–14 years were conﬁrmed with oral
ﬂuid.
In contrast, despite a small increase in incidence in 2015,
cases in infants aged <3 months and 3–5 months were slightly
lower in the most recent 3-year period (60.4 and 12.7 per
100 000, respectively) relative to the 3 years before the maternal
program was introduced (62.5 and 14.0 per 100 000).
In line with this, annual deaths in infants diagnosed with per-
tussis have remained lower than the peak of 14 in 2012, al-
though there has been some variation in case fatality rate in
young infants over the years (Table 1). In 14 of the 16 deaths
that occurred between 2013 and 2015, the infant’s mother
had not received pertussis vaccine in pregnancy. Only 2 of the
infants born after the introduction of the maternal program had
a mother who had been vaccinated during pregnancy but in
both cases too close to delivery (<10 days) to confer optimal
passive protection in the infant. All but 1 of the deaths since
the maternal program was introduced have occurred in unim-
munized infants; 1 infant had received the ﬁrst dose of pertus-
sis-containing vaccine 8 days before recorded onset, and the
infant’s mother, who was eligible for vaccination in pregnancy,
was unimmunized.
Maternal Pertussis Vaccine Effectiveness
Updated Estimates of Maternal Vaccine Effectiveness
Against Infant Disease, Prior to Primary Immunization.
By the end of September 2015, a total of 398 cases aged <24
months and born from 1 October 2012 with onset by 30 Sep-
tember 2014 had been conﬁrmed (excluding serology only).
Maternal vaccination status was unknown in 46 cases and so
these were excluded. For this analysis, only those 253 infants
aged <93 days and with no childhood doses recorded were re-
tained. For the primary analysis of vaccination at least 7 days
prior to birth, 8 individuals born in week 40 of 2012 did not
contribute, as they could not have been vaccinated more than a
week before birth. Two cases vaccinated within a week of birth
were also excluded for this analysis. This left 243 cases, of
whom 35 had been born to vaccinated mothers, giving an overall
effectiveness of 91% (95% conﬁdence interval [CI], 88%–94%)
and for infants <3 months of age and 90% (95% CI, 86%–
93%) for infants <2 months of age. Vaccine effectiveness remains
high at 82% (95% CI, 74%–88%) for infants <2 months of age,
despite reducing coverage by a relative 20% (Table 2).
Maternal Pertussis Vaccine Effectiveness by Timing of
Vaccination. Vaccine effectiveness was also calculated for
vaccination at least 4 weeks before delivery, 1–3 weeks before
delivery, and within a week of delivery to 2 weeks after delivery
(Table 3). For these analyses, cases from week 40 of 2012 were
included. Vaccine effectiveness was 91% for infants whose
mothers received vaccine at least 4 weeks prior to delivery
(95% CI, 88%–94%) and 1–3 weeks prior to delivery (95% CI,
80%–96%). For the small number of infants whose mothers re-
ceived vaccine up to 1 week before delivery and within 1–2
weeks following delivery, VE declines to 43% (95% CI, −35%
to 76%).
Maternal Vaccine Effectiveness Against Infant Death
From Pertussis. From the 243 cases, there were a total of 11
deaths in infants, of whom 1 infant had a mother who had been
vaccinated at least 1 week before delivery, but <10 days. The av-
erage matched coverage was 67.9%. To calculate VE, average
matched coverage was applied to the 95% binomial CI on 1/
11 (0.2%–31.2%). VE against death was calculated at 95%
(95% CI, 79%–100%), consistent with the overall VE against
disease of 91%.
Maternal Vaccine Effectiveness Against Disease for
dTaP5-IPV and dTaP3-IPV. The maternal VE of dT5aP-
IPV and dT3aP-IPV did not signiﬁcantly differ and was
Table 1. Summary of Deaths in Infant With Laboratory-Confirmed
Pertussis Cases From All Sources, England Only, 2009–2015
Age at Onset 2009 2010 2011 2012 2013 2014 2015
<2 mo,
unvaccinated
mother
2 1 5 12 3 5 2
2–5 mo,
unvaccinated
mother
1 0 0 2 0 1 1
<2 mo,
vaccinated
mother
0 1 1
2–5 mo,
vaccinated
mother
0 0 0
Total deaths 3 1 5 14 3 7 4
CFR in infants <3
mo (%)
3.0% 1.8% 3.0% 3.4% 3.5% 7.1% 3.1%
Abbreviation: CFR, case fatality rate.
Table 2. Maternal Pertussis Vaccine Effectiveness Estimates for Vaccinated at Least 1 Week Before Delivery
Age Cases Vaccinated/Total Average Matched Coverage VE (95% CI) VE Reducing Coverage by Relative 20% (95% CI)
<3 mo 35/243 64.8% 91% (88–94) 85% (78–89)
<2 mo 31/192 64.3% 90% (86–93) 82% (74–88)
Abbreviations: CI, confidence interval; VE, vaccine effectiveness.
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calculated at 93% (95% CI, 89%–95%) and 88% (95% CI, 79%–
93%), respectively (Table 4).
Maternal Vaccine Effectiveness in Infants Commencing Primary
Infant Series
A total of 73 children had received a childhood vaccine and
were born after week 40 of 2012. Of these 73 children, the moth-
ers of 26 had been vaccinated. Of the 73 children, 43 had re-
ceived 1 dose, 12 had received 2 doses, and 18 had received 3
doses of their primary pertussis vaccines. Onset date was miss-
ing in 17 children (11, 2, and 4 of whom had had 1, 2, and 3
doses, respectively).
Estimated VE (Table 5) indicates that maternal vaccine con-
tinues to offer protection to children who have received a ﬁrst
primary dose (VE, 82% [95% CI, 65%–91%]). For infants who
have received 2 doses, the protection conferred through mater-
nal immunization declines to 69% (95% CI, 8%–90%), and after
completion of the primary infant schedule the protection from
maternal immunization, which is based on small numbers, de-
clines further, although the point estimate remains above 0%.
With these lower effectiveness estimates, the effect of reducing
coverage by a relative 20% is greater, with the estimated effec-
tiveness from maternal vaccination declining from 69% to
43% for infants who have received 2 doses of their primary se-
ries. Results were similar when only including cases with a
known onset date.
DISCUSSION
Maternal pertussis vaccination was introduced in the United
Kingdom in 2012 in response to the highest number of infant
deaths observed for more than a decade. Despite very short time
scales for implementation of this outbreak response measure,
the program was well accepted, with routine coverage in En-
gland close to 60% in the ﬁrst year of the program. This level
of coverage has been sustained in the following 2 years, al-
though coverage from 2 data sources has shown ﬂuctuations
during the year with coverage increasing during the winter
months. This pattern was particularly evident in 2013 and
2014. One potential explanation is that the increase in coverage
coincides with the timing of the seasonal inﬂuenza vaccination
program for pregnant women. Unlike the maternal pertussis
vaccination program, in England there is an active call and recall
system for the seasonal inﬂuenza vaccination program, and both
programs are predominantly delivered in primary care. As a re-
sult, women who attend for inﬂuenza vaccination can be as-
sessed for their eligibility for pertussis vaccine. While
considerable efforts are focusing on improving coverage, up to
40% of the antenatal population in England remain unvaccinat-
ed, and this reﬂects the continuing number of infant deaths
since the program was introduced in 2012. This is of particular
concern, given that pertussis continues to circulate at height-
ened levels with the average population incidence for the
3-year period following the introduction of the program being
almost 2 times higher than that for the 3-year period preceding
Table 3. Maternal Pertussis Vaccine Effectiveness Estimates, by Timing
of Vaccination
Timing of Vaccination
Cases
Vaccinated/Total
AverageMatched
Coverage VE (95% CI)
28 d before delivery 31/229 64.1% 91% (88–94)
7–27 d before delivery 4/213 16.2% 91% (80–96)
0–6 d before or 1–13 d
after delivery
3/179 2.7% 43% (−35 to 76)
Abbreviations: CI, confidence interval; VE, vaccine effectiveness.
Table 4. Maternal Pertussis Vaccine Effectiveness, by Vaccine Product
Vaccine
Cases
Vaccinated/
Total
Average
Matched
Coverage VE (95% CI)
VE Reducing
Coverage by Relative
20% (95% CI)
dT5aP-IPV 20/172 63.1% 93% (89–95) 87% (80–92)
dT3aP-IPV 15/71 69.3% 88% (79–93) 78% (62–88)
Abbreviations: CI, confidence interval; dT3aP, diphtheria–tetanus–3-component acellular
pertussis vaccine; dT5aP, diphtheria–tetanus–5-component acellular pertussis vaccine;
IPV, inactivated polio vaccine; VE, vaccine effectiveness.
Table 5. Vaccine Effectiveness of a Maternal Dose at Least 7 Days Before Birth for Infants Commencing Primary Series
Primary Doses
Cases’ Mothers
Vaccinated/Total
Case
Coverage
Average Matched
Coverage VE (95% CI)
VE Reducing Coverage by Relative 20%
(95% CI)
Exactly 1 dose 11/43 25.6% 64.3% 82% (65–91) 68% (37–83)
Exactly 2 doses 5/12 41.7% 70.3% 69% (8–90) 43% (−73 to 81)
Exactly 3 doses 10/18 55.6% 64.1% 29% (−112 to 76) −21% (−242 to 57)
Exactly 1 dose (onset
known)
9/32 28.1% 65.5% 81% (57–91) 65% (24–84)
Exactly 2 doses (onset
known)
5/10 50.0% 69.2% 56% (−33 to 86) 20% (−156 to 75)
Exactly 3 doses (onset
known)
7/14 50.0% 64.4% 46% (−96 to 85) 6% (−216 to 72)
Abbreviations: CI, confidence interval; VE, vaccine effectiveness.
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2012. This was observed for all age groups >6 months, although
the incidence in infants <3 months of age being targeted by the
program has been held at low levels, providing ecological evi-
dence of a program impact. In 2015, an increase in laboratory-
conﬁrmed cases was observed across all age groups in England,
in line with the usual cyclical peaks every 3–4 years; however, the
increased incidence in children aged 5–9 years is of note, as this is
the only age group where the incidence in 2015 exceeds the 2012
peak and is the ﬁrst cohort of children in the United Kingdom
who were fully primed and boosted with acellular pertussis vac-
cines only.
The impact of the maternal program on infant disease is fur-
ther supported by the assessment of VE. This relied on the rapid
enhancement of existing surveillance systems to derive the ﬁrst
estimates of protection from the maternal program in England,
1 year following its introduction. Vaccine effectiveness of the
program was calculated at >90% for infants whose mothers re-
ceived vaccine at least 1 week prior to delivery, using both the
screening method and case-control study approaches [10, 11],
and this level of protection appears to have been sustained in
the 3 years following the introduction of the program despite
the change to a another acellular vaccine with a different anti-
gen composition.
The screening method used in this study has the advantage of
comparing the vaccination status of cases to a large population,
but can only adjust for the potential confounders of maternal
age and time period and assumes that vaccination coverage
data are representative. The evaluation using the screening
method found very similar results to a matched case-control
study using many of the same cases where controls were
matched to the general practice of the cases [10, 11]. This is con-
sistent with the coverage data used from CPRD being represen-
tative and no confounding by general practice or region.
Furthermore, we are not aware of other factors likely to have
a large confounding effect.
The evidence generated from the evaluation of the maternal
program in England has been extremely valuable in informing
recommendations on pertussis control strategies by the WHO
and national immunization advisory committees [1]. Many
countries have recommended pertussis vaccination for preg-
nant women including the United States, Australia, New Zea-
land, Belgium, and Spain, although evaluation of their
programs with respect to protection against clinical disease is
ongoing.
Although evidence of high effectiveness and safety of the ma-
ternal pertussis program in England has been extremely encour-
aging and informed the decision by the JCVI in 2014 to
continue the program for a further 5 years, a number of ques-
tions still remain. This includes the inﬂuence of timing of ma-
ternal vaccination on protection against disease in infants. Our
analysis suggests that similarly high levels of protection are con-
ferred to infants whose mothers received vaccine at least
4 weeks and 1–4 weeks prior to delivery. The levels of protection
decline signiﬁcantly for the relatively low number of infants
whose mothers received vaccine around the time of delivery,
and any residual protection that may be conferred is likely to
reﬂect the indirect protection from reduced maternal exposure.
The second question that has been raised is how effective ma-
ternal vaccination is against infant deaths. Although deaths
have continued to occur since the introduction of the program,
these have almost exclusively occurred in infants born to unvac-
cinated mothers and in the 2 exceptions, maternal vaccination
did not occur in the optimal period to confer protection to the
infant. The estimated 95% effectiveness against infant deaths
adds to the evidence base for the recommendation to offer
women pertussis vaccine during pregnancy.
Changes to the vaccine product offered through the program
in England in 2014, from the 5-component acellular pertussis
vaccine to a 3-component acellular pertussis vaccine (with a
higher PT and FHA antigen content), also offered an opportu-
nity to estimate the VE of the 2 products. Our analysis suggests
that both the 3- and 5-component vaccines provide high levels
of protection for infants <2 months of age and, although the
point estimates of effectiveness of the 3-component vaccine is
5% lower than that of the 5-component vaccine, they are not
signiﬁcantly different. A randomized clinical trial in England
comparing maternal and infant responses in pregnant women
vaccinated with each vaccine is nearing completion and will
provide additional valuable information.
Finally, one of the key issues that remains an area of contin-
uing discussion is the impact and clinical signiﬁcance of blunt-
ing of the infants’ immune response from maternally derived
antibodies. Although immunogenicity studies from North
America and England have demonstrated lower antibody re-
sponses post–primary series in infants born to mothers who re-
ceived vaccine during pregnancy, the clinical signiﬁcance of this
blunting effect remains unknown, given the lack of agreed cor-
relates of protection for pertussis. To address this question, the
additional protection conferred through maternal immuniza-
tion for infants who have commenced their primary infant
schedule can be estimated. This analysis suggests that high levels
of protection are conferred to infants who have received their
ﬁrst dose of the primary series. After the third infant dose,
the numbers are small and there is no longer evidence of pro-
tection. However, importantly, the estimates are above 0%,
which indicates that there is no evidence of greater risk of dis-
ease after primary immunization, in those infants whose moth-
ers received vaccine during pregnancy. Although this provides
some reassurance, given the low numbers, this question requires
ongoing assessment to determine if this continues to be the
case. It is important to note that some protective effect may
be expected to last beyond the primary vaccination series in
the child due to the mother being less likely to transmit. This
may mask an interference effect in the direct protection in the
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child. To assess the direct protection in the child, the VE of the
primary doses themselves should be estimated among children
whose mothers have been vaccinated; however, the numbers
currently are too small to make this assessment.
In the United Kingdom, the pertussis program for pregnant
women has been recommended as an outbreak response mea-
sure, and a routine recommendation by JCVI requires evidence
of cost effectiveness. A recent analysis has indicated that while
the cost effectiveness of this program is highly dependent on the
future incidence of infant disease, which is uncertain, maternal
vaccination is the only certain way of protecting vulnerable in-
fants from birth [20].
In February 2016, the JCVI updated its recommendations on
the timing of vaccination during pregnancy, indicating that vac-
cine can be offered earlier than the 28- to 32-week optimal win-
dow that had previously been recommended [21]. This was
largely based on data from immunogenicity studies suggesting
that vaccinating earlier in pregnancy, from 16 weeks, results in
high levels of transplacental transfer of maternal antibodies to
the infant [22]. From 1 April 2016, women are recommended
to receive pertussis vaccine from 20 weeks (although it may be
given from 16 weeks), and it is hoped that widening the window
of opportunity for vaccination will help to improve coverage of
the program in England and therefore maximize this life saving
intervention for young infants.
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